TITLE

Johnson & Johnson and Pfizer show strong earnings growth

AUTHOR(S)
Martinez, Marialba
PUB. DATE
April 2002
SOURCE
Caribbean Business;4/25/2002, Vol. 30 Issue 17, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the financial performance of drug companies Johnson & Johnson and Pfizer Co. during the first quarter of 2002. Corporate profits; Sales; Growth targets and strategies.
ACCESSION #
6568231

 

Related Articles

  • A Broad Product Mix Serves Pfizer and J&J Well in 2002. Jarvis, Lisa // Chemical Market Reporter;1/27/2003, Vol. 263 Issue 4, p8 

    Reports on the financial performance of pharmaceutical companies, Pfizer Inc. and Johnson & Johnson Inc. during the fourth quarter of 2002. Earnings increase of 46 percent for Pfizer; Pharmaceutical sales growth experienced by Johnson & Johnson; Financial forecast for the two companies in 2003.

  • Pharma majors end 2005 upbeat. Mirasol, Feliza // Chemical Market Reporter;1/30/2006, Vol. 269 Issue 4, p28 

    The article reports on the financial performance of major pharmaceutical companies in the United States in 2005. Pfizer Inc., Novartis and Johnson & Johnson posted strong fourth quarter earnings in 2005 despite financial difficulties. Pfizer's fourth quarter earnings per share declined 12...

  • Pharmaceutical Giants Post Hefty First Quarter Results. Mirasol, Feliza // Chemical Market Reporter;04/26/99, Vol. 255 Issue 17, p4 

    Offers a look at the 1999 first quarter results of pharmaceutical companies in the United States (US). US sales of Viagra from Pfizer Inc.; Results for Prozac from Lilly & Co.; Revenues of Pfizer and Lilly & Co.; Revenues of Johnson & Johnson; Earnings of SmithKline Beecham; Profits of...

  • Pfizer and Johnson & Johnson profit from active drug sales.  // Chemical Market Reporter;04/20/98, Vol. 253 Issue 16, p18 

    Reports on the financial performance of drug firms Pfizer Inc. and Johnson & Johnson Co. for the first quarter of 1998. Total revenues; Growth in sales; Worldwide sales of Pfizer's major pharmaceutical products.

  • TOP 20 PHARMA REPORT.  // Contract Pharma;Jul/Aug2010, Vol. 12 Issue 6, p34 

    The article offers the ranking of the top 20 pharmaceutical companies based on their revenues in 2009. On the top of the list is Pfizer Inc. with 45,448,000 million dollars, followed by Sanofi-Aventis Ltd. with 40,871,000 million dollars. Meanwhile, GlaxoSmithKline earned the fourth spot having...

  • J&J marketing spend falls, but Olysio fuels a sales hike. D. W. // Medical Marketing & Media;Jun2014, Vol. 49 Issue 6, p13 

    The article reports on the 7.7% growth of pharmaceutical sales of Johnson & Johnson in the U.S. and more than 12% worlwide, during the first quarter of 2014, which is accompanied by lower quarterly investment in marketing and selling expenses.

  • Eli Lilly, J&J, Pfizer Post Strong 1Q Results, S-P Reports Lower Sales. Krause, Carey // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p24 

    Reports on the earnings growth of Eli Lilly & Co., Johnson & Johnson and Pfizer Inc. for the first quarter of 2001. Reason for the earnings growth; Statistics of the earnings; Details on the revenue of Schering-Plough.

  • Top 20 pharmaceutical companies.  // Modern Healthcare;8/16/2004, Vol. 34 Issue 33, p40 

    Presents the top 20 pharmaceutical companies in the U.S. based on sales from April 2003 to March 2004. Total sales of the Pfizer company; Percent growth of the GlaxoSmithKline company; Market share of the Johnson & Johnson company.

  • Leading Drug Makers Post Good 2nd Quarter Growth. Mirasol, Feliza // Chemical Market Reporter;07/26/99, Vol. 256 Issue 4, p6 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics